A detailed study confirms the effectiveness modest of an antiviral against the Covid-19

Une étude détaillée confirme l’efficacité modeste d’un antiviral contre le Covid-19

Washington | More than three weeks after the announcement of a senior american scientist that an experimental drug called remdesivir accelerating the recovery of the hospitalized patients of the Covid-19, the study detailing the results was released on Friday evening in a medical journal listed.

Anthony Fauci, director of the Institute of allergy and infectious diseases (NIAID), which has led the clinical trial of a thousand patients in 10 countries, had said on 29 April, in the oval Office of the White House, as preliminary data showed ” that the remdesivir (had) a clear, meaningful, and positive to reduce the time of recovery.”

After verification by a reading committee, the New England Journal of Medicine published the article detailing the results confirming the announcement made at the White House, who had caused a glimmer of hope in the world, in the absence of other effective therapy against the novel coronavirus.

The remdesivir, injected daily intravenously for 10 days, accelerated the recovery of the hospitalized patients of the Covid-19, compared to placebo: 11 days, up from 15 in median. Were considered to be recovered, the patients return home.

The effect was most important in the hospitalized patients but who were not on an artificial respirator. The authors conclude that it is better to start the treatment of remdesivir before the disease progresses to the point of requiring an artificial respirator.

The antiviral drug, developed formerly in vain against Ebola, has also attracted less adverse effects than placebo.

The remdesivir has also seemed to reduce mortality: 7.1% of patients in the group remdesivir are dead in 14 days, compared to 11.9% in the placebo group, but this result is just below the threshold of statistical reliability, and we cannot exclude the possibility that the difference is due to chance.

In all cases, the remdesivir does not provide a guarantee of survival, insist the authors of the test. “It is clear that antiviral treatment may not be sufficient alone “, they write.

The key to dealing with Covid-19 will, without a doubt, combinations of treatments, the remdesivir with other antiviral or other types of therapies.

The laboratory that developed the remdesivir, Gilead, said Friday the results of its own clinical trials would be published in the near future. One of them would show that a treatment of five days, instead of 10 days, would also be effective, according to Merdad Parsey, chief medical officer of Gilead Sciences.

In the United States, the Agency for medicines (FDA) has authorized the 1st of may the use in emergency remdesivir in hospitals, followed by Japan, while Europe is considering a similar decision.

Share Button